Related Experiment Video
Updated: May 6, 2026

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
LRRK2 deficiency mitigates amyloid β deposition-mediated pathology in a murine Alzheimer's disease model by
Qiuyang Zhang1,2, Hsuan Lo3,4, Yue Song2,5
1Department of Neurology, Fuzhou Second General Hospital, 47 Shangteng Road, Fuzhou, 350007, China.
Abstract:
Leucine-rich repeat kinase 2 (LRRK2), primarily expressed in microglia, is responsible for the modulation of innate immune responses and associated with various immunological disorders. Available evidence documents that though as the predominant etiological factor for familial Parkinson's disease, LRRK2 mutations rarely occur in Alzheimer's disease (AD) and that LRRK2 polymorphism is potentially associated with late-onset AD. However, the role of LRRK2 in AD immunopathogenesis remains unknown. In this study, we investigated the impact of LRRK2 deficiency on cognitive function, Aβ plaque accumulation, and plaque-associated neuropathology in AD mice. The results revealed that compared with the 5xFAD mice, the 8-month-old 5xFAD;LRRK2-/- mice reported improved learning and memory, reduced cerebral and hippocampal Aβ plaque burden, and decreased microglia and astrocytes within the central region of hippocampal Aβ plaques. The 5xFAD;LRRK2-/- mice also showed a decrease in several complement and proinflammatory cytokines in the brain, indicating an altered microglial phenotype. Furthermore, the absence of LRRK2 prevented synaptic loss and restored the disrupted equilibrium between excitatory and inhibitory synapses in the 5xFAD mice. These findings suggest that LRRK2 may play an essential role in Aβ plaque pathology, glial responses to plaques, and neuronal dysfunction in the brain of the 5xFAD mice and that a genomic transgene-blockade of LRRK2 may reprogram the microglial responsivity, thus mitigating the neuropathological and behavioral deficits in AD mice. The 5xFAD;LRRK2-/- mice reduced cognitive impairment in the Morris water maze test compared with the 5xFAD mice. The protective effect of LRRK2 inhibition is not dependent on the APP production process or Aβ degradation. Conversely, 5xFAD;LRRK2-/- mice enhanced microglial phagocytosis, reducing Aβ aggregation and glial activation. Additionally, compared with the 5xFAD, the 5xFAD;LRRK2-/- mice exhibited preserved synaptic structure, characterized by higher PSD95 expression, lower C1qa/C3 expression in both excitatory and inhibitory synapses, upregulated VGLUT1 expression, and downregulated VGAT expression.
Insights
Leucine-rich repeat kinase 2 (LRRK2) deficiency improved cognitive function and reduced amyloid plaques in Alzheimer
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Leucine-rich repeat kinase 2 (LRRK2) is implicated in innate immunity and neurological disorders.
- LRRK2 mutations are linked to Parkinson's disease; its role in Alzheimer's disease (AD) immunopathogenesis is unclear.
- LRRK2 polymorphism may be associated with late-onset AD.
Purpose of the Study:
- To investigate the impact of LRRK2 deficiency on cognitive function, amyloid-beta (Aβ) plaque accumulation, and neuropathology in AD mice.
- To explore how LRRK2 absence affects microglial responses and synaptic integrity in an AD mouse model.
Main Methods:
- Utilized 5xFAD transgenic mice with and without LRRK2 deficiency (5xFAD;LRRK2-/-).
- Assessed cognitive function using the Morris water maze test.
- Quantified Aβ plaque burden, glial cell activation (microglia, astrocytes), cytokine levels, and synaptic markers.
Main Results:
- LRRK2 deficiency in 5xFAD mice improved learning and memory compared to 5xFAD controls.
- Reduced cerebral and hippocampal Aβ plaque burden and decreased glial activation were observed in 5xFAD;LRRK2-/- mice.
- Absence of LRRK2 preserved synaptic structure, reduced neuroinflammation, and enhanced microglial phagocytosis of Aβ.
Conclusions:
- LRRK2 plays a critical role in Aβ pathology, glial responses, and neuronal dysfunction in the 5xFAD mouse model.
- Genomic blockade of LRRK2 can reprogram microglial responsivity, mitigating neuropathological and behavioral deficits in AD.
- LRRK2 inhibition offers a potential therapeutic strategy for Alzheimer's disease by modulating neuroinflammation and synaptic integrity.

